NCT00833066View on ClinicalTrials.gov

Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

November 30, 2009

Conditions
Seasonal Allergic Rhinoconjunctivitis
Interventions
BIOLOGICAL

gpASIT+TM

entero-coated capsules containing 25µg of gpASIT+TM

BIOLOGICAL

Placebo

placebo entero-coated capsules

BIOLOGICAL

gpASIT+TM

entero-coated capsules containing 100µg of gpASIT+TM

BIOLOGICAL

gpASIT+TM

entero-coated capsules containing 400µg of gpASIT+TM

Trial Locations (4)

1020

University Hospital Brugmann, Brussels

3000

University Hospital Gasthuisberg, Leuven

4000

University Hospital Sart Tilman, Liège

9000

University Hospital Ghent, Ghent

Sponsors

Lead Sponsor

BioTech Tools S.A.
All Listed Sponsors
lead

BioTech Tools S.A.

INDUSTRY